SCHEMBL3014665

SCHEMBL3014665

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(Cc3c(C)cccc3C)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
ALDH1A1 P00352 3/20 0.51
RECQL P46063 1/20 0.51
LMNA P02545 4/20 0.50
TSHR P16473 2/20 0.50
POLB P06746 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
TP53 P04637 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
GAA P10253 2/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPK1 P28482 1/20 0.44
ALOX12 P18054 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014984 0.93 MAPT (0.50) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3019130 0.91 ALDH1A1 (0.49) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3002552 0.91 ALDH1A1 (0.50) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3014655 0.90 ALDH1A1 (0.64) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3002429 0.90 MAPT (0.44) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3002376 0.90 ALDH1A1 (0.51) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3011154 0.88 TRPV4 (0.44) MAPTALDH1A1LMNATSHRPOLB
SCHEMBL3003251 0.88 ALDH1A1 (0.48) MAPTALDH1A1RECQLLMNATSHR
SCHEMBL3008166 0.88 LMNA (0.54) MAPTALDH1A1LMNATSHRPOLB
SCHEMBL3007189 0.88 ALDH1A1 (0.52) MAPTALDH1A1RECQLLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.